Business Description
Pro Medicus Ltd
ISIN : AU000000PME8
Share Class Description:
ASX:PME: Ordinary SharesDescription
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 74.86 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 192.65 | |||||
| Beneish M-Score | -2.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 33.4 | |||||
| 3-Year EBITDA Growth Rate | 34.5 | |||||
| 3-Year EPS without NRI Growth Rate | 38.9 | |||||
| 3-Year FCF Growth Rate | 34.1 | |||||
| 3-Year Book Growth Rate | 31.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 28.09 | |||||
| Future 3-5Y Total Revenue Growth Rate | 25.48 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 85.32 | |||||
| 9-Day RSI | 83.79 | |||||
| 14-Day RSI | 80.37 | |||||
| 6-1 Month Momentum % | 63.63 | |||||
| 12-1 Month Momentum % | 113.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.98 | |||||
| Quick Ratio | 5.98 | |||||
| Cash Ratio | 4.48 | |||||
| Days Inventory | 69.52 | |||||
| Days Sales Outstanding | 96.22 | |||||
| Days Payable | 4361.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.17 | |||||
| Dividend Payout Ratio | 0.44 | |||||
| 3-Year Dividend Growth Rate | 39.1 | |||||
| Forward Dividend Yield % | 0.19 | |||||
| 5-Year Yield-on-Cost % | 0.81 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 0.19 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.81 | |||||
| Operating Margin % | 69.49 | |||||
| Net Margin % | 51.29 | |||||
| FCF Margin % | 46.64 | |||||
| ROE % | 51.14 | |||||
| ROA % | 36.87 | |||||
| ROIC % | 99.75 | |||||
| ROC (Joel Greenblatt) % | 594.84 | |||||
| ROCE % | 57.55 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 288.77 | |||||
| Forward PE Ratio | 219.1 | |||||
| PE Ratio without NRI | 288.77 | |||||
| Shiller PE Ratio | 687.19 | |||||
| Price-to-Owner-Earnings | 260.7 | |||||
| PEG Ratio | 9.05 | |||||
| PS Ratio | 148.13 | |||||
| PB Ratio | 127.04 | |||||
| Price-to-Tangible-Book | 141.87 | |||||
| Price-to-Free-Cash-Flow | 317.68 | |||||
| Price-to-Operating-Cash-Flow | 291.33 | |||||
| EV-to-EBIT | 211.41 | |||||
| EV-to-Forward-EBIT | 115.87 | |||||
| EV-to-EBITDA | 196.49 | |||||
| EV-to-Forward-EBITDA | 108.1 | |||||
| EV-to-Revenue | 146.9 | |||||
| EV-to-Forward-Revenue | 109.35 | |||||
| EV-to-FCF | 289.26 | |||||
| Price-to-Projected-FCF | 33.74 | |||||
| Price-to-DCF (Earnings Based) | 8.39 | |||||
| Price-to-DCF (FCF Based) | 9.23 | |||||
| Price-to-Median-PS-Value | 3.03 | |||||
| Price-to-Peter-Lynch-Fair-Value | 11.55 | |||||
| Price-to-Graham-Number | 42.69 | |||||
| Price-to-Net-Current-Asset-Value | 174.36 | |||||
| Price-to-Net-Cash | 278.55 | |||||
| Earnings Yield (Greenblatt) % | 0.48 | |||||
| FCF Yield % | 0.31 | |||||
| Forward Rate of Return (Yacktman) % | 20.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pro Medicus Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 161.429 | ||
| EPS (TTM) (A$) | 0.791 | ||
| Beta | 1.49 | ||
| Volatility % | 23.72 | ||
| 14-Day RSI | 80.37 | ||
| 14-Day ATR (A$) | 6.35563 | ||
| 20-Day SMA (A$) | 208.3 | ||
| 12-1 Month Momentum % | 113.01 | ||
| 52-Week Range (A$) | 85.6 - 235.09 | ||
| Shares Outstanding (Mil) | 104.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pro Medicus Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pro Medicus Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pro Medicus Ltd Frequently Asked Questions
What is Pro Medicus Ltd(ASX:PME)'s stock price today?
The current price of ASX:PME is A$228.41. The 52 week high of ASX:PME is A$235.09 and 52 week low is A$85.60.
When is next earnings date of Pro Medicus Ltd(ASX:PME)?
The next earnings date of Pro Medicus Ltd(ASX:PME) is 2025-02-14 Est..
Does Pro Medicus Ltd(ASX:PME) pay dividends? If so, how much?
The Dividend Yield %  of Pro Medicus Ltd(ASX:PME) is 0.17% (As of Today), Highest Dividend Payout Ratio of Pro Medicus Ltd(ASX:PME) was 0.65. The lowest was 0.33. And the median was 0.43. The  Forward Dividend Yield % of Pro Medicus Ltd(ASX:PME) is 0.19%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers